KeasClinical Studies ApS: Financial statements 2023
CVR: 40794492
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
KeasClinical Studies ApS (CVR 40794492) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -7,500 and a net result of DKK -7,486 compared with DKK -10,427 the year before. Equity in the 2023 report amounted to DKK 93,277. The solvency ratio was 92%.
- Gross Profit
- DKK -7,500
- Profit/Loss
- DKK -7,486
- Equity
- DKK 93,277
- Total Assets
- DKK 101,411
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | -8 t. | -7 t. | 93 t. | - |
| 2022 | - | -23 t. | -10 t. | 303 t. | - |
| 2021 | - | 151 t. | 113 t. | 663 t. | 0 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
KeasClinical Studies ApS has published its annual report for 2022. Gross profit came to DKK -23,277, and the net result was DKK -10,427.
About KeasClinical Studies ApS
KeasClinical Studies ApS is a Danish company of the type Anpartsselskab based in Aarhus C, founded in 2019. The company is registered under the industry Andre liberale, videnskabelige og tekniske tjenesteydelser i.a.n.. The company was previously named Blitz Technology ApS. The management consists of Lone Bliksted Gitz-Johansen. The company is owned by Mette Albinus Grønbæk and Blitz Holding ApS. The company has 1 employee (2020). In 2025, the company reported a gross profit of DKK -23,492 and a net result of DKK -14,372 compared with DKK -607 the year before. Equity in the 2025 report amounted to DKK 78,298.